Below are the financial statements of Madrigal Pharmaceuticals, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 |
|---|---|---|
| Product revenue, net | 180.13a | 0a |
| Operating expenses | — | — |
| Cost of sales | -6.23a | 0a |
| Research and development | -236.72a | -272.35a |
| Selling, general and administrative | -435.06a | -108.15a |
| Total operating expenses | -678.01a | -380.5a |
| Loss from operations | -497.88a | -380.5a |
| Interest income | 46.65a | 19.58a |
| Interest expense | -14.67a | -12.71a |
| Net loss | -465.89a | -373.63a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Madrigal Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.